Evidence map›Paper›PMID 38709419›Full record

ArticleJournal of gastrointestinal cancer2024

Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.

Zahra Mosaferi, Majid Pirestani, Ehsan Arefian, Goli Gojani, Nastaran Kavousinasab, Parto Karimi, Azam Deilami, Zahra Abrehdari-Tafreshi

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zahra MosaferiDepartment of Cell and Molecular Biology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
Majid PirestaniParasitology & Entomology Dept, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ehsan ArefianDepartment of Microbiology, School of Biology, College of Sciences, University of Tehran, Tehran, Iran.
Goli GojaniNational Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Nastaran KavousinasabDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Parto KarimiDepartment of Chemistry, Faculty of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Azam DeilamiDepartment of Cell and Molecular Biology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
Zahra Abrehdari-TafreshiDepartment of Cell and Molecular Biology, School of Biology, College of Sciences, University of Tehran, P. O. Box, Tehran, 14155-6455, Iran. zahra.abrehdari@ut.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with colorectal cancer can benefit from anti-EGFR (epidermal growth factor receptor) therapy. However, this therapy is not effective for treating colorectal cancers with constitutive activating mutations in the KRAS, NRAS, and BRAF genes. Molecular analysis of tumor tissue frequently informs treatment decisions for colorectal cancer. This study aims to identify KRAS, NRAS, and BRAF mutations in Iranian patients diagnosed with colorectal cancer and to assess the prevalence of these mutations relative to the tumor differentiation stage within these populations.

methodsFrom April 2018 to December 2022, 2000 specimens from patients with colorectal cancer were collected. Data on sex, age, and tumor differentiation stage were recorded for all samples. For mutation detection, the KRAS and NRAS exons (2, 3, and 4) were amplified using the Diatech kit, and a specific primer was used to amplify BRAF exon 15. Pyrosequencing was then performed.

resultsAnalysis of samples revealed that 1105 specimens (55.3%) contained mutations in at least one of the screened genes. Among the genes studied, the highest occurrence was the KRAS mutation at 47.4%, followed by NRAS at 5.3% and BRAF at 2.7%. Most KRAS mutations were found in exon 2 (89.7%), with the G12D mutation being the most prevalent at 32% of cases. There was a significant difference in the rate of KRAS mutations in women (52.5%) compared to men (43.5%) (P =  0.02). For NRAS, the majority mutations were observed in exon 3 (76.2%), with the Q61H mutation being the most prevalent at 28.5% of cases. There were no significant associations between the clinicopathological parameters and mutations.

conclusionThe study's findings indicate a rising frequency of mutations in these genes in Iran, highlighting the need to screening mutations in the main exons of all three genes for effective colorectal cancer treatment strategies.

Indexed as

Colorectal NeoplasmsGTP PhosphohydrolasesMembrane ProteinsMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overExonsFemaleHumansIranMaleMiddle AgedBRAF protein, humanGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAFColorectal cancerKRASNRAS

Identifiers

PMID38709419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.